Session Coverage

Emerging diagnostic algorithms and advances in therapy could transform management of alpha-1 antitrypsin deficiency, an often-overlooked genetic disease that affects the lungs and the liver, said Malik Khurram Khan, MD, FCCP.

Rheumatologic diseases can be difficult to recognize when encountered in the ICU. Missing these diagnoses can delay life-saving therapies and significantly impact patients’ outcomes, said Rami Batarseh, MD, FCCP.

CHEST 2026 Honor and Memorial Lectures will recognize individuals who have advanced work in critical care, interventional medicine, mechanical ventilation, medical education, and other areas.

Sessions spanning lung cancer diagnosis, interventional pulmonology, and radiology will reflect the fast-moving field and the real-world questions clinicians face every day in practice, said Jose De Cardenas, MD, FCCP.

Simulation courses during CHEST 2026 will empower clinicians to solve the problems they encounter in day-to-day practice using the latest procedural equipment and techniques.

For clinicians who treat airways disease, CHEST 2026 will offer a guideline-driven curriculum built around what’s new, immediately applicable, and possibly even controversial, said Dharani K. Narendra, MD, FCCP.

Sessions at CHEST 2026 will include talks on pulmonary hypertension (PH), pulmonary embolism (PE), chronic thromboembolic pulmonary hypertension (CTEPH), heart failure with preserved ejection fraction (HFpEF), and more, said Oksana Shlobin, MD, FCCP.

At CHEST 2026, more than 120 “Advanced” sessions will meet mid- and late-career clinicians at their level, said Mauricio Danckers, MD, FCCP.

By arriving one day early to CHEST 2026, clinicians can immerse themselves in an educational experience unlike any other, said Allison Wynes, DNP, CCAPP, FCCP.

Sessions at CHEST 2026 will challenge clinicians to rethink traditional techniques and explore new applications in critical care medicine, said Alice Gallo de Moraes, MD, FCCP.